Blurbs Goldman Sachs Sticks to Its Buy Rating for Adt (ADT) November 6, 2023 Share FacebookTwitterPinterestWhatsApp Must read Nvidia CEO aiming to set up base in Vietnam, Reuters reports December 10, 2023 Utz Brands to host investor day December 10, 2023 Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term... December 10, 2023 Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral... December 10, 2023 Goldman Sachs Sticks to Its Buy Rating for Adt (ADT) Source link Share FacebookTwitterPinterestWhatsApp Previous articleOppenheimer Sticks to Their Hold Rating for Mueller Water Products (MWA)Next articleHold Rating on Liberty Media Formula One (FWONK) Amid Mixed 3Q23 Results and Increased LVGP Costs More articles Universal Music Group (UMGNF) was downgraded to a Hold Rating at Kepler Capital December 10, 2023 Kepler Capital Keeps Their Buy Rating on Genfit (GNFTF) December 10, 2023 Surgery Partners (SGRY): A Solid Buy on Long-Term Growth and Strategic Expansions Despite Near-Term Challenges December 9, 2023 Latest article Nvidia CEO aiming to set up base in Vietnam, Reuters reports December 10, 2023 Utz Brands to host investor day December 10, 2023 Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term... December 10, 2023 Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral... December 10, 2023 Autolus Therapeutics presents clinical data updates at ASH Annual Meeting 2023 December 10, 2023